Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicity

International Journal of Cancer

Volumn 51, Issue 3, 1992, Pages 433-438

  Keller, Roland P ^a,c   Altermatt, Hans J ^b   Donatsch, Peter ^a   Zihlmann, Hans ^a   Laissue, Jean A ^b   Hiestand, Peter C ^a  

^a Sandoz Pharma Ltd   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN DERIVATIVE; ETOPOSIDE; VALSPODAR; CYCLOSPORIN A; VERAPAMIL;

ADENOCARCINOMA; ADULT; ANIMAL; ARTICLE; BLOOD; COLON TUMOR; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG SCREENING; GERMFREE ANIMAL; HUMAN; MALE; MOUSE; MOUSE STRAIN; NUDE MOUSE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ADULT; ANIMAL; COLONIC NEOPLASMS; CYCLOSPORINS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; HUMAN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0026611746     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910510316     Document Type: Article

References (24)

1. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P‐glycoprotein by a vinblastine analog
2. Heavy water delays growth of human carcinoma in nude mice
3. Pharmacokinetics in patients with abnormal renal and hepatic function
4. Identification of the multidrug‐resistance‐related P‐glycoprotein as a cyclosporine binding protein
5. SDZ PSC 833, a non‐immunosuppressive cyclosporine: its potency in overcoming P‐glycoprotein‐mediated multidrug‐resistance of murine leukemia
6. The effect of verapamil on the pharmacokinetics of adriamycin
7. Enhancement of antitumor activity of etoposide by dihydropyridines on drug‐sensitive and drug‐resistant leukemia in mice
8. Interaction of cyclosporin A with antineoplastic agents
9. Cyclosporine metabolism in human liver: identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs
10. Etoposide (E) combined with cyclosporin A (CsA) in soft‐tissue sarcoma patients resistant to conventional chemotherapy
11. Molecular biology of multidrug resistance in human cells
12. Glutathione‐S‐transferases: gene structure, regulation, and biological function
13. 6‐alkylguanine‐DNA alkyltransferase as potential indicators of constitutive drug resistence in human colorectal tumors
14. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC‐52
15. Microsomal interaction and inhibition of lipid peroxidation by etoposide (VP 16–213): implications for mode of action
16. Activity of a new glycosidic lignan derivative (VP 16–213) related to podophyllotoxin in experimental tumors
17. Expression of cytochrome P 450S in tumor‐derived cell lines
18. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
19. A possible role for cyclosporins in cancer chemotherapy
20. Distribution of multidrug resistance‐associated P‐glycoprotein in normal and neoplastic human tissues. Analysis of 3 monoclonal antibodies recognizing different epitopes of the P‐glycoprotein molecule
21. Mechanism of action of antitumor drug etoposide: a review
22. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin‐A in an attempt to reverse multidrug resistance
23. Potentiation of etoposide and vincristine by two synthetic 1,4‐dihydropyridine derivatives in multidrug‐resistant and atypical multi‐drug‐resistant and human cancer cells
24. What determines the substrate specificity of the multidrug‐resistance pump?